Creating a novel cell therapy platform with best-in-class processes

The evolution of cell therapy

Enter your contact information and we will get back to you and tell more.
17TH OF JANUARY 2023

ALDER THERAPEUTICS LICENSES TWO CELL THERAPY PROGRAMS FROM DUKE-NUS AND BIOLAMINA  

17th January 2023, Stockholm, Sweden. In two separate exclusive license agreements, Alder Therapeutics AB secured access to Intellectual Property and know-how for two state-of-the-art methods to manufacture retinal and cardiac cell therapeutic products.

Read the whole pressrelease here (PDF)
27TH OF SEPTEMBER 2022

ALDER THERAPEUTICS SECURES 20 MSEK SEED FUNDING  

Alder Therapeutics secured 20 MSEK seed financing from two top tier Swedish life-science investors Flerie Invest AB and Linc AB (publ). Upon reaching certain development milestones, Alder will receive an additional 14.4 MSEK. The proceeds will be used to develop two of Alder’s initial stem cell therapy programs and to build the team to drive these programs forward.

Read the whole pressrelease here (PDF)

The next era in cell therapy is here

Cell therapy has taken a long time to evolve. In cell therapy the main challenge is to find the optimal manufacturing process that delivers the best therapeutic cells every single time. The Alder Edge helps to optimize pluripotent stem cell differentiation processes, delivering more homogeneous and highest quality cell therapy products, every single time.
The Alder Edge helps reproducibility and makes your cell manufacturing processes more robust.

Our Team‍

CEO – Kristian Tryggvason
Over a decade in the cell therapy field. Three years at a drug development company. Founded and built a successful cell therapy reagents company. Scouted and licensed a promising cell therapy project to a large pharmaceutical company with Phase I clinical trial commencing soon.
COO – Stijn Heessen
A decade of academic research and 14 years of increasingly senior positions in the pharma industry. Experience includes global Regulatory Affairs and Business Development & Strategy at GSK, Boehringer Ingelheim, Sanofi and Perrigo.
CTO – Ricardo Baptista
A true pioneer and expert in the therapeutic cell manufacturing field with a PhD in process engineering and work experience from CCRM, Cell Therapy Catapult, Cellectis and Procella. He combines the CMC knowledge together with clinical and regulatory stragies.

Do you have a differentiation protocol that needs some polishing or are you interested to learn more?

Enter your contact information and we will get in touch!
Thank you! We get in contact with you as soon as possible!
Oops!
Something went wrong while submitting the form. Please try again!
ALDER Therpeutics  |  Nanna Svartz väg 4  |  SE-171 65 Solna  |  SWEDEN  |  +46 (0)70 743 22 33  |  info@aldertx.com
Copyright © Alder Therapeutics